S&P also affirmed the “A-” long-term rating on HFHS’s $366.59 million of series 2006A bonds and $303.43 million of series 2009 bonds.
“HFHS has seen a significant turnaround in fiscal 2015 (audited results through Dec. 31, 2015), which management attributes to stable patient volumes and significant progress on its ‘Strength and Sustainability’ plan to reduce costs and improve value,” said S&P credit analyst J. Kevin Holloran.
“The positive outlook reflects our view that during the outlook period, HFHS will continue to build on recently improved operations, and that the associated cash flow will enable it to bolster key balance sheet metrics,” Mr. Holloran added.
More articles on healthcare finance:
ER physicians criticize new Fla. law banning surprise medical charges
UC-Berkeley School of Public Health mulls closing medical school program to cut costs
MACRA Roadmap: 9 questions on a post-SGR world, answered
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
